We are monitoring the impact of COVID-19 on Europe Psoriasis Drugs Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1637
Share on
Share on

Europe Psoriasis Drugs Market Research Report - Segmented By Drug Type, Route of Administration, Target, & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - industry Analysis on Size, Share, Trends and Growth Forecast (2020 to 2025)

Pulished: February, 2020
ID: 1637
Pages: 140

Europe Psoriasis Drugs Market Size (2020 to 2025)

The size of the European Psoriasis Drugs Market is expected to worth USD 3.94 billion by 2025 from USD 2.76 billion in 2020, showcasing a CAGR of 7.36% from 2020 to 2025.

Psoriasis is no communicable inflammatory skin condition that alters the life cycle of skin cells by speeding up the growth of cells on the skin's surface. The rapid development of cells produces thick, silvery scales and makes the skin red, dry, flaky, and itchy. Currently, no permanent cure is available for the disease,

However, preventative measures can be adopted to slow down skin cells' growth on the surface of the skin. Psoriasis can be treated either with pharmaceuticals or biopharmaceuticals therapies through the topical and systemic process.

These medications are administered either by applying on the skin or consumed orally or through injections that specifically block parts of the immune system by specifically targeting Tumor Necrosis Factor, Phosphodiesterase Type 4, Interleukin, among others. In Europe, approximately 3.7 million people are affected by psoriasis as per the European Federation of Pharmaceutical Industries and Associations.

The growth of the Psoriasis Drugs market is majorly driven by factors such as increasing public awareness, approval of new drugs (interleukin-17 inhibitor, Taltz - ixekizumab by Eli Lily), and boost in psoriasis Research and Development investment. The key restraints of the market are the high cost involved in drug development, patent expiry of brand name drugs, side effects from the systemic and biologics medication, and health insurance issue.

This research report on the European Psoriasis Drugs Market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Pharmaceuticals
  • Biopharmaceuticals

By Route of Administration: 

  • Topical
  • Systemic
    • Oral
    • Intravenous
    • Others

By Target: 

  • Tumour Necrosis Factor (TNF)
  • Phosphodiesterase Type 4 (PDE4)
  • Interleukin

By Country: 

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Prominent companies dominating the European Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).


                1.1 Market Definition     

                1.2 Study Deliverables   

                1.3 Base Currency, Base Year and Forecast Periods   

                1.4 General Study Assumptions 

2. Research Methodology                    

                2.1 Introduction        

                2.2 Research Phases       

2.2.1 Secondary Research                           

2.2.2 Primary Research                 

2.2.3 Econometric Modelling                      

2.2.4 Expert Validation                  

                2.3 Analysis Design  

                2.4 Study Timeline   

3. Overview                

                3.1 Executive Summary 

                3.2 Key Inferences  

                3.3 Epidemology       

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)             

                4.1 Market Drivers   

                4.2 Market Restraints     

                4.3 Key Challenges  

                4.4 Current Opportunities in the Market       

5. Market Segmentation                       

                5.1 Drug Type    

5.1.1 Introduction                           

5.1.2 Pharmaceuticals                   

5.1.3 Biopharmaceuticals                             

5.1.4  Y-o-Y Growth Analysis, By Drug Type                          

5.1.5  Market Attractiveness Analysis, By Drug Type                        

5.1.6  Market Share Analysis, By Drug Type                         

                5.2 Route of Administration

5.2.1 Introduction                           

5.2.2 Topical                      

5.2.3 Systemic                  




5.2.4  Y-o-Y Growth Analysis, By Route of Administration                              

5.2.5  Market Attractiveness Analysis, By Route of Administration                            

5.2.6  Market Share Analysis, By Route of Administration                             

                5.3 Target    

5.3.1 Introduction                           

5.3.2 Tumour Necrosis Factor (TNF)                        

5.3.3 Phosphodiesterase Type 4 (PDE4)                

5.3.4 Interleukin                              

5.3.5 Others                      

5.3.6  Y-o-Y Growth Analysis, By Target                 

5.3.7  Market Attractiveness Analysis, By Target                               

5.3.8  Market Share Analysis, By Target                 

6. Geographical Analysis                       

                6.1 Introduction        

6.1.1 Regional Trends                    

6.1.2 Impact Analysis                     

6.1.3 Y-o-Y Growth Analysis                        
 By Geographical Area     
 By Product           
 By Type 
 By Application    
 By Indication       

6.1.4  Market Attractiveness Analysis                     
 By Geographical Area     
 By Product           
 By Type 
 By Application    
 By Indication       

6.1.5  Market Share Analysis                      
 By Geographical Area     
 By Product           
 By Type 
 By Application    
 By Indication       

                6.2 U.K  

                6.3 Spain      

                6.4 Germany      

                6.5 Italy        

                6.6 France   

7.Strategic Analysis                 

                7.1 PESTLE analysis  

7.1.1 Political                     

7.1.2 Economic                 

7.1.3 Social                         

7.1.4 Technological                         

7.1.5 Legal                          

7.1.6 Environmental                       

                7.2 Porter’s Five analysis       

7.2.1 Bargaining Power of Suppliers                        

7.2.2 Bargaining Power of Consumers                    

7.2.3 Threat of New Entrants                     

7.2.4 Threat of Substitute Products and Services                              

7.2.5 Competitive Rivalry within the Industry                     

8.Market Leaders' Analysis                  

                8.1 Johnson & Johnson  

8.1.1 Overview                 

8.1.2 Product Analysis                   

8.1.3 Financial analysis                  

8.1.4 Recent Developments                       

8.1.5 SWOT analysis                       

8.1.6 Analyst View                          

                8.2 Novartis International AG     

                8.3 Pfizer Inc      

                8.4 Merck and Co. Inc     

                8.5 Celgene Corporation       

                8.6 Janssen Biotech Inc          

                8.7 Stiefel Laboratories Inc   

                8.8 Takeda Pharmaceutical Company Limited      

                8.9 Amgen  

                8.10 AbbVie        

9.Competitive Landscape                     

                9.1 Market share analysis     

                9.2 Merger and Acquisition Analysis

                9.3 Agreements, collaborations and Joint Ventures  

                9.4 New Product Launches  

10.Market Outlook and Investment Opportunities                   


                a) List of Tables 

                b) List of Figures       

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Psoriasis Drugs Market, By Systemic, From 2020 to 2025 (USD Billion)
  2. Europe Oral Systemic Route Market, By Region, From 2020 to 2025 (USD Billion)
  3. Europe Intravenous Systemic Route Market, By Region, From 2020 to 2025 (USD Billion)
  4. Europe Others Systemic Route Market, By Region, From 2020 to 2025 (USD Billion)
  5. U.K. Psoriasis Drugs Market, By Systemic, From 2020 to 2025 (USD Billion)
  6. Germany Psoriasis Drugs Market, By Systemic, From 2020 to 2025 (USD Billion)
  7. France Psoriasis Drugs Market, By Systemic, From 2020 to 2025 (USD Billion)
  8. Italy Psoriasis Drugs Market, By Systemic, From 2020 to 2025 (USD Billion)
  9. Spain Psoriasis Drugs Market, By Systemic, From 2020 to 2025 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample